$ Value
—
Shares
2,034,133
Price
—
Filed
Apr 22
Insider
Name
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Title
—
CIK
0002080343
Roles
Transaction Details
Transaction Date
2026-04-20
Code
C
Table
Non-Derivative
Ownership
Direct
Equity Swap
No
Shares After
2,034,133
Footnotes
The reported securities are directly held by Hengrui (USA) Ltd. Hengrui (USA) Ltd. is a wholly-owned subsidiary of Jiangsu Hengrui Pharmaceuticals Co., Ltd. | The Series A-2 convertible preferred stock and Series A-2 convertible non-voting preferred stock (collectively, the "Preferred Stock") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock.
Filing Info
Jiangsu Hengrui Pharmaceuticals Co., Ltd.'s History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-04-20 | KLRA | C | — |
| 2026-04-20 | KLRA | C | — |
| 2026-04-20 | KLRA | C | $0 |
| 2026-04-20 | KLRA | C | $0 |
Other Insiders at KLRA (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
| Kaplan Andrew T. / BAIN CAPITAL INVESTORS LLC | $134.4M | — | 2026-04-20 |
| Bain Capital Life Sciences Investors, LLC / Koppel Adam | $25.0M | — | 2026-04-20 |
| RTW INVESTMENTS, LP | $8.0M | — | 2026-04-20 |
| BAIN CAPITAL INVESTORS LLC | — | — | 2026-04-20 |
| MILLIGAN JOHN F | — | — | 2026-04-16 |
|
Renaud Ronald C JR
CEO & President
|
— | — | 2026-04-16 |
| MACKAY MARTIN | — | — | 2026-04-16 |
| Koppel Adam | — | — | 2026-04-20 |
|
Pagan Douglas W.
Chief Financial Officer
|
— | — | 2026-04-16 |
| Bain Capital Life Sciences Investors, LLC | — | — | 2026-04-20 |
|
Burgess Paul D.
See Remarks
|
— | — | 2026-04-16 |
|
Cloghessy Paula
Chief People Officer
|
— | — | 2026-04-16 |
| Kaplan Andrew T. | — | — | 2026-04-20 |
| Clyburn Frank | — | — | 2026-04-16 |
| Hite Christopher | — | — | 2026-04-16 |
|
Akamine Scott
Chief Legal Officer
|
— | — | 2026-04-16 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | — | — | 2026-04-20 |
|
Coleman Jamie Beth
Chief Commercial Officer
|
— | — | 2026-04-16 |
|
Wasserman Scott M.
Chief Medical Officer
|
— | — | 2026-04-16 |